Transcenta Nachrichten und Aktivitäten
Präsenz
Headquarters: China
Transcenta ist ein Unternehmen, das unter dem Börsenticker 6628 (CN) gelistet ist.
Führungskräfte
Siehe das Organigramm mit seine 14 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Transcenta
- Xueming Qian, Chief Executive Officer and Chairman of the Board
- Helen Chen, Independent Non-Executive Director
- Jiasong Tang, Independent Non-Executive Director
Letzte Veränderungen der Führungskräfte auf Transcenta
- Christopher Hwang, wurde beim Unternehmen als Head of Global Partnerships, HiCB Platform eingestellt (Nachrichten veröffentlicht am 31, März 2026).
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Transcenta nachzuverfolgen.
Biotechnologie
Transcenta hat 2.428 Konkurrenten , einschließlich Lonza (Schweiz), Vertex Pharmaceuticals (USA) und Eurofins (Luxemburg).
Popular M&A news in Biotechnologie
- Eli Lilly has announced the acquisition of AtaiBeckley (veröffentlicht am 17, Juli 2026).
- GSK hat Nuvalent erworben (veröffentlicht am 17, Juli 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (veröffentlicht am 15, Juli 2026).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Transcenta
- Transcenta Reports Receipt of HiCB Out-licensing Milestone Payment and Steady CDMO Business Growth-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta’s Partner Inhibrx Reports Positive Updated CRC Data for Ozekibart and Announces U.S. BLA Submission for Chondrosarcoma-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeuti
- Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-line G/GEJ Cancer at ESMO Asia-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma, with a BLA Submission Planned for 2026-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Announces the Appointment of Tyler Marciniak as Senior Vice President of Capital Markets, Investor Relations and Corporate Communications-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Strengthens Promise for Osemitamab (TST001) for G/GEJ Cancer with OS Data from First-Line Triple Combo Trial Unveiled at 2025 ASCO Annual Meeting-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Debuts Promising Anti-Tumor Activity of Novel FGFR2b Targeting ADC with Site-Specific Conjugated Topo I Inhibitor Payload in Preclinical Tumor Models at AACR 2025-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- View more press releases Close
Social media about Transcenta
- Transcenta auf Wikipedia, Google News & Yahoo Finance
- Transcenta auf LinkedIn, X (Twitter) & YouTube
